Atezolizumab and Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma: Pharmacokinetic and Safety Assessments Based on Hepatic Impairment Status and Geographic Region

Atezolizumab and Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma: Pharmacokinetic and Safety Assessments Based on Hepatic Impairment Status and Geographic Region

Introduction: Phase 1b GO30140 and phase 3 IMbrave150 studies evaluated first-line atezolizumab + bevacizumab for unresectable hepatocellular carcinoma (HCC). Here, we evaluated pharmacokinetics (PK) and safety by hepatic impairment status and geographic region. Methods: Patients received atezolizum...

Full description

Bibliographic Details
Main Authors: Colby S. Shemesh, Phyllis Chan, Hui Shao, Derek-Zhen Xu, Daniel Combs, Shweta Vadhavkar, René Bruno, Benjamin Wu
Format: Article
Language:English
Published: Karger Publishers 2021-06-01
Series:Liver Cancer
Subjects:
atezolizumab
bevacizumab
hepatic impairment
geographic region
clinical pharmacology
Online Access:https://www.karger.com/Article/FullText/515817

Internet

https://www.karger.com/Article/FullText/515817

Similar Items